

Attorney Docket No. 4409.214-US
Serial No. 09/772,607
Filed: January 30, 2001
Inventors: Jonassen et al.
Via Facsimile No.: 517-273-8300

Amendments To The Claims

The listing of claims will replace all prior versions, and listings, of the claims in the application.

Listing Of Claims:

Claims 1-47 (Cancelled).

Claim 48 (Previously presented) A derivative of GLP-1 or an analog thereof wherein a lipophilic substituent having 8 to 40 carbon atoms and optionally having an amino group is optionally via a spacer attached to the C-terminal amino acid of GLP-1 or the analog thereof and wherein the spacer is Lys, Glu or Asp, or Glu-Lys wherein the Lys is attached to the C-terminal amino acid of GLP-1 or the analog thereof, or Asp-Lys wherein the Lys is attached to the C-terminal amino acid of GLP-1 or the analog thereof.

Claim 49 (Previously presented) The derivative of claim 48, wherein the lipophilic substituent has 12 to 35 carbon atoms.

Claim 50 (Previously presented) The derivative of claim 48, wherein the lipophilic substituent is an acyl group of a straight chain fatty acid.

Claim 51 (Previously presented) The derivative of claim 48, wherein the lipophilic substituent is attached to the C-terminal amino acid via a spacer.

Claim 52 (Previously presented) The derivative of claim 51, wherein the lipophilic substituent is an acyl group of a straight chain fatty acid.

Claim 53 (Previously presented) The derivative of claim 52, wherein the spacer is Lys and the lipophilic substituent is $-\text{CO}(\text{CH}_2)_m\text{CH}_3$ wherein m is an integer from 8 to 18 and is attached to the ϵ -amino group of the spacer.

Claim 54 (Previously presented) The derivative of claim 52, wherein the spacer is Glu-Lys- and the lipophilic substituent is $-\text{CO}(\text{CH}_2)_p\text{CH}_3$ wherein p is an integer from 10 to 16 and is attached to Glu.

Attorney Docket No. 4409.214-US
Serial No. 09/772,607
Filed: January 30, 2001
Inventors: Jonassen et al.
Via Facsimile No.: 517-273-8300

Claim 55 (Previously presented) The derivative of claim 50, wherein the lipophilic substituent is tetradecanoyl.

Claim 56 (Previously presented) The derivative of claim 55, which is SEQ ID NO:2, His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys [N^ε-γ-Glu(N^α-tetradecanoyl)-OH]-OH.

Claim 57 (Previously presented) The derivative of claim 48, wherein the lipophilic substituent has a free carboxylic acid when attached to the C-terminal amino acid of GLP-1 or the analog thereof.

Claim 58 (Previously presented) The derivative of claim 57, wherein the lipophilic substituent is attached to the C-terminal amino acid of GLP-1 or the analog thereof via a spacer.

Claim 59 (Previously presented) The derivative of claim 58, wherein the spacer is Lys.